The founders of Molecular Partners discovered and initially developed the DARPin® base technology at the University of Zurich. Molecular Partners licenses the platform on an exclusive basis. The company continues to protect its proprietary position by filing for patent protection for its platform in Europe, the United States and other important jurisdictions. Molecular Partners’ patent portfolio includes several patent families that cover further development of the DARPin® technology, particular DARPin® proteins and product candidates. Certain key patents for Molecular Partners’ protection have been granted in various jurisdictions.
DARPin® is a registered trademark owned by Molecular Partners AG.